Bio Rad Laboratories, Inc. BIO
We take great care to ensure that the data presented and summarized in this overview for BIO-RAD LABORATORIES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BIO
View all-
Vanguard Group Inc Valley Forge, PA1.91MShares$646 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.55MShares$525 Million0.01% of portfolio
-
Van Eck Associates Corp1.3MShares$442 Million0.55% of portfolio
-
Veritas Asset Management LLP1.09MShares$368 Million3.03% of portfolio
-
First Eagle Investment Management, LLC713KShares$242 Million0.5% of portfolio
-
Select Equity Group, L.P. New York, NY708KShares$240 Million0.95% of portfolio
-
Dimensional Fund Advisors LP Austin, TX654KShares$222 Million0.05% of portfolio
-
State Street Corp Boston, MA636KShares$215 Million0.01% of portfolio
-
Earnest Partners LLC Atlanta, GA606KShares$205 Million0.92% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny584KShares$198 Million0.1% of portfolio
Latest Institutional Activity in BIO
Top Purchases
Top Sells
About BIO
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Insider Transactions at BIO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 20
2024
|
Sedat Evran EVP, Global Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
335
-28.2%
|
$115,910
$346.37 P/Share
|
Oct 20
2024
|
Sedat Evran EVP, Global Supply Chain |
BUY
Exercise of conversion of derivative security
|
Direct |
1,044
+46.77%
|
-
|
Sep 06
2024
|
Andrew J. Last EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,000
-28.41%
|
$987,000
$329.94 P/Share
|
Sep 06
2024
|
Andrew J. Last EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+22.13%
|
$897,000
$299.24 P/Share
|
Sep 04
2024
|
James Barry EVP, President, LSG |
SELL
Open market or private sale
|
Direct |
623
-81.01%
|
$205,590
$330.49 P/Share
|
Sep 03
2024
|
Michael Crowley EVP, GBL Commercial Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
283
-3.35%
|
$94,522
$334.31 P/Share
|
Sep 03
2024
|
Michael Crowley EVP, GBL Commercial Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
557
+6.18%
|
-
|
Sep 03
2024
|
Norman D Schwartz Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,241
-0.28%
|
$414,494
$334.31 P/Share
|
Sep 03
2024
|
Norman D Schwartz Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,320
+0.53%
|
-
|
Sep 03
2024
|
James Barry EVP, President, LSG |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-9.21%
|
$26,052
$334.31 P/Share
|
Sep 03
2024
|
James Barry EVP, President, LSG |
BUY
Exercise of conversion of derivative security
|
Direct |
217
+20.39%
|
-
|
Sep 03
2024
|
Colleen Corey EVP, Global Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
177
-0.95%
|
$59,118
$334.31 P/Share
|
Sep 03
2024
|
Colleen Corey EVP, Global Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
495
+2.58%
|
-
|
Sep 03
2024
|
Schwartz Allison Director |
SELL
Payment of exercise price or tax liability
|
Direct |
27
-2.03%
|
$9,018
$334.31 P/Share
|
Sep 03
2024
|
Schwartz Allison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
56
+4.03%
|
-
|
Sep 02
2024
|
Michael Crowley EVP, GBL Commercial Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
155
-1.93%
|
$52,235
$337.32 P/Share
|
Sep 02
2024
|
Michael Crowley EVP, GBL Commercial Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
434
+5.11%
|
-
|
Sep 02
2024
|
Norman D Schwartz Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
965
-0.22%
|
$325,205
$337.32 P/Share
|
Sep 02
2024
|
Norman D Schwartz Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,805
+0.41%
|
-
|
Sep 02
2024
|
James Barry EVP, President, LSG |
SELL
Payment of exercise price or tax liability
|
Direct |
95
-13.1%
|
$32,015
$337.32 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 31.1K shares |
---|---|
Bona fide gift | 530 shares |
Payment of exercise price or tax liability | 10.2K shares |
---|---|
Open market or private sale | 10.7K shares |
Bona fide gift | 7.1K shares |